Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FGEN

DatePrice TargetRatingAnalyst
8/8/2023$4.00 → $2.00Neutral → Underperform
BofA Securities
6/26/2023Buy → Hold
Stifel
6/26/2023Buy → Neutral
BofA Securities
6/26/2023Outperform → Mkt Perform
Raymond James
6/26/2023Outperform → Mkt Perform
William Blair
6/2/2023$23.00 → $32.00Hold → Buy
Stifel
1/31/2023Mkt Perform → Outperform
William Blair
1/26/2023$35.00Mkt Perform → Outperform
Raymond James
More analyst ratings

$FGEN
Press Releases

Fastest customizable press release news feed in the world

See more
  • FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

    Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected by mid-2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 2H 2025 FibroGen to host conference call and webcast presentation today at 5:00 PM ET SAN FRANCISCO, March 17, 2025

    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

    SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To acc

    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

     Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structure Company's cash runway extended into 2027 Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025Preliminary unaudited cash, cash equivalents, and accounts receivable of $121.1 million as of December 31, 2024FibroGen to host conference call and webcast presentation today at

    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FGEN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FGEN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$FGEN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FGEN
SEC Filings

See more

$FGEN
Leadership Updates

Live Leadership Updates

See more
  • FibroGen Appoints David DeLucia as Chief Financial Officer

    SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024. Reporting to Chief Executive Officer Thane Wettig, DeLucia will lead and oversee FibroGen's global finance organization. He has most recently served as FibroGen's Vice President, Head of Corporate Financial Planning and Analysis, Investor Relations, and Treasury. "Having worked closely with David for the past two and a half years, I am extremely confident he has the breadth and depth of experiences and capabili

    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

    SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024. "Deyaa's leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need," said Thane Wettig, Chief Executive Officer of FibroGen. "We are excited to welcome him

    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FibroGen Announces Leadership Transition

    Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced the appointment of Thane Wettig as the Company's interim Chief Executive Officer effective as of July 23, 2023. Mr. Wettig has served as FibroGen's Chief Commercial Officer and a key member of the senior leadership team since June 2020. Mr. Wettig succeeds Chief Executive Officer Enrique Conterno, who resigned due to personal reasons. To support Mr. Wettig, Mr. Conterno will serve as a Special Advisor to the CEO during a transition period. "Than

    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FGEN
Financials

Live finance-specific insights

See more
  • FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

    Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), expected by mid-2025 Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC expected in 2H 2025 FibroGen to host conference call and webcast presentation today at 5:00 PM ET SAN FRANCISCO, March 17, 2025

    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

    SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To acc

    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

     Purchase price represents enterprise value of $85 million plus FibroGen net cash held in China at closing, currently estimated to be approximately $75 millionUpon close, FibroGen will repay its term loan to Morgan Stanley Tactical Value, further simplifying the Company's capital structure Company's cash runway extended into 2027 Company to continue to advance its oncology pipeline, with the initiation of the Phase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) in 2Q 2025Preliminary unaudited cash, cash equivalents, and accounts receivable of $121.1 million as of December 31, 2024FibroGen to host conference call and webcast presentation today at

    $FGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$FGEN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more